Adalimumab for treatment of pyoderma gangrenosum.
Pomerantz
R G
RG
Husni
M E
ME
Mody
E
E
Qureshi
A A
AA
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab